Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 May 30:16:447-459.
doi: 10.2147/CEOR.S460912. eCollection 2024.

Oral Prostacyclin Pathway Agents Used in PAH: A Targeted Literature Review

Charles D Burger  1 , Yuen Tsang  2 , Marie Chivers  3 , Riya Vijay Vekaria  3 , Gurinderpal Doad  2   4 , Nikki Atkins  3 , Sumeet Panjabi  2   4
Affiliations
Review

Oral Prostacyclin Pathway Agents Used in PAH: A Targeted Literature Review

Charles D Burger et al. Clinicoecon Outcomes Res. .

Abstract

Purpose: Pulmonary arterial hypertension (PAH) is a rare and progressive pulmonary vascular disease that can result in right heart failure and death. Oral prostacyclins play an important role in the management of intermediate-low risk PAH. This targeted literature review (TLR) aimed to identify and compare evidence supporting use of oral prostacyclin pathway agents (PPAs: selexipag and oral treprostinil) in intermediate-low risk PAH.

Methods: A targeted literature review was conducted. Literature databases (MEDLINE, Embase, and Cochrane reviews) were searched for studies describing clinical practice and treatment outcomes for oral treprostinil and selexipag globally, published in English (2012 to 2022). Electronic searches were supplemented by manual-searches of targeted conferences (2020 to 2022), and reference lists of identified publications were reviewed. One reviewer assessed studies for eligibility.

Results: In total, 95 publications met inclusion criteria: 47 full-text articles (selexipag n = 22; oral treprostinil n = 16; selexipag and oral treprostinil n = 9) and 48 conference materials. Selexipag and oral treprostinil target the prostacyclin pathway differently; their label-supporting trials had different primary endpoints (disease progression and hospitalization vs exercise capacity and disease progression), differing baseline therapy (0, 1 or 2 vs 0 or 1 baseline treatments), titration duration and dosing (personalized dose capped at 1600 ug twice daily (BID) vs increasing doses over time with no maximum dose), respectively. While both oral PPAs have demonstrated reduced risk of disease progression, only selexipag showed reduction in hospitalization rates. Oral PPAs have been shown to reduce healthcare costs in real-world clinical practice. This difference is reflected in labeled indications.

Conclusion: Given differences in trial- and real-world outcomes, number of prior therapies, and dosing, personalizing the choice of oral PPA is critical to maximizing the benefit for individual patients.

Keywords: outcomes; pulmonary hypertension; selexipag; treprostinil.

Plain language summary

PAH is a condition that causes heart failure. It is important to take medicines to slow down this process. For people with early disease, there are some medicines that can be taken as a tablet rather than as an injection to slow down disease progression. The differences between two of the tablet options – selexipag and oral treprostinil, are unclear. We reviewed publications describing how, when and why these medicines are used and how well they work, to improve our understanding of the value of these medicines to people with PAH.

PubMed Disclaimer

Conflict of interest statement

Dr Charles Burger reports personal fees from Janssen, personal fees from INSMED, personal fees from Merck, and non-financial support from United Therapeutics, during the conduct of the study. Yuen Tsang is a former employee and owns stock in Johnson & Johnson. Dr Marie Chivers, Nikki Atkins and Ms Riya Vekaria report employment with Avalere Health which was in receipt of payment from Janssen for this element of the study. Dr Gurinderpal Doad and Dr Sumeet Panjabi are employees and stockholders of Johnson & Johnson, the company that markets oral selexipag. The authors report no other conflicts of interest in this work.

Figures

Figure 1
Figure 1
PRISMA diagram.
Figure 2
Figure 2
Real-world evidence studies describing proportions of patient using selexipag and oral treprostinil within a combination regimen. (a) illustrates the proportions of patients taking selexipag as a monotherapy or within dual- or triple-combination regimens in reported studies; (b) illustrates the proportions of patients taking oral treprostinil as a monotherapy or within dual- or triple-combination regimens in reported studies. aThis value has been calculated based on patient baseline characteristics, assuming the background therapy has been supplemented with one additional therapy rather than replaced.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Hassoun PM, Taichman DB. Pulmonary Arterial Hypertension. N Engl J Med. 2021;385(25):2361–2376. doi:10.1056/NEJMra2000348 - DOI - PubMed
    1. Lai YC, Potoka KC, Champion HC, Mora AL, Gladwin MT. Pulmonary arterial hypertension: the clinical syndrome. Circ Res. 2014;115(1):115–130. doi:10.1161/CIRCRESAHA.115.301146 - DOI - PMC - PubMed
    1. Austin ED, Kawut SM, Gladwin MT, Abman SH. Pulmonary hypertension: NHLBI workshop on the primary prevention of chronic lung diseases. Ann Am Thorac Soc. 2014;11(Suppl 3):S178–85. doi:10.1513/AnnalsATS.201312-443LD - DOI - PMC - PubMed
    1. Badesch DB, Raskob GE, Elliott CG, et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest. 2010;137(2):376–387. doi:10.1378/chest.09-1140 - DOI - PubMed
    1. Burger CD, Ghandour M, Padmanabhan Menon D, Helmi H, Benza RL. Early intervention in the management of pulmonary arterial hypertension: clinical and economic outcomes. Clinicoecon Outcomes Res. 2017;9:731–739. doi:10.2147/CEOR.S119117 - DOI - PMC - PubMed